Avant and Celldex in $115mm merger
Immunotherapeutics companies Avant and Celldex Therapeutics (majority-owned by Medarex) have agreed to merge in an all-stock deal worth about $115mm.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.